Initial biological classification of Lewy body diseases: No consensus on terminology.
作者信息
Lang Anthony E, Höglinger Günter U, Adler Charles H, Berg Daniela, Klein Christine, Outeiro Tiago Fleming, Poewe Werner, Postuma Ron, Stoessl A Jon
机构信息
Edmond J. Safra Program in Parkinson's Disease and the Rossy PSP Centre, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada.
Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU), Munich, Germany.
出版信息
Alzheimers Dement. 2025 Feb;21(2):e14449. doi: 10.1002/alz.14449. Epub 2024 Dec 28.
Abstract
摘要
相似文献
1
Initial biological classification of Lewy body diseases: No consensus on terminology.路易体疾病的初步生物学分类：术语尚无共识。
Alzheimers Dement. 2025 Feb;21(2):e14449. doi: 10.1002/alz.14449. Epub 2024 Dec 28.
2
Cholinesterase inhibitors for dementia with Lewy bodies.用于路易体痴呆的胆碱酯酶抑制剂。
Cochrane Database Syst Rev. 2003;2003(3):CD003672. doi: 10.1002/14651858.CD003672.
3
Evidence for the existing American Nurses Association-recognized standardized nursing terminologies: a systematic review.现有美国护士协会认可的标准化护理术语的证据：一项系统评价。
Int J Nurs Stud. 2014 Aug;51(8):1160-70. doi: 10.1016/j.ijnurstu.2013.12.004. Epub 2013 Dec 18.
4
Defining Clinical Course of Patients Evaluated for Pediatric Acute-Onset Neuropsychiatric Syndrome: Phenotypic Classification Based on 10 Years of Clinical Data.确定接受小儿急性起病神经精神综合征评估患者的临床病程：基于10年临床数据的表型分类
Dev Neurosci. 2025;47(4):270-286. doi: 10.1159/000545598. Epub 2025 Apr 4.
5
Memantine for Lewy body disorders: systematic review and meta-analysis.美金刚治疗路易体痴呆：系统评价和荟萃分析。
Am J Geriatr Psychiatry. 2015 Apr;23(4):373-383. doi: 10.1016/j.jagp.2013.11.007. Epub 2013 Dec 4.
6
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.用于路易体痴呆、帕金森病痴呆及帕金森病认知障碍的胆碱酯酶抑制剂
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD006504. doi: 10.1002/14651858.CD006504.pub2.
7
Substantia Nigra Iron Deposition in Lewy Body Disease: A Magnetic Resonance Imaging and Neuropathology Study.路易体病中的黑质铁沉积：一项磁共振成像与神经病理学研究
Mov Disord. 2025 Jun 23. doi: 10.1002/mds.30265.
8
Speech sound disorder or DLD (phonology)? Towards a consensus agreement on terminology.言语障碍或 DLD（语音学）？术语达成共识的途径。
Int J Lang Commun Disord. 2024 Nov-Dec;59(6):2131-2145. doi: 10.1111/1460-6984.12989. Epub 2023 Dec 7.
9
The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic review.路易体痴呆功能性多巴胺能闪烁显像诊断性能的系统评价更新。
Eur J Nucl Med Mol Imaging. 2023 Jun;50(7):1988-2035. doi: 10.1007/s00259-023-06154-y. Epub 2023 Mar 15.
10
Latin American consensus on psoriasis severity classification.拉丁美洲银屑病严重程度分类共识。
An Bras Dermatol. 2025 May-Jun;100(3):539-547. doi: 10.1016/j.abd.2024.09.010. Epub 2025 Apr 29.
引用本文的文献
1
Implementing a tridimensional diagnostic framework for personalized medicine in neurodegenerative diseases.为神经退行性疾病的个性化医疗实施三维诊断框架。
Alzheimers Dement. 2025 Feb;21(2):e14591. doi: 10.1002/alz.14591.
2
Protein misfolding: understanding biology to classify and treat synucleinopathies.蛋白质错误折叠：通过理解生物学来对突触核蛋白病进行分类和治疗。
J Neural Transm (Vienna). 2025 Feb 11. doi: 10.1007/s00702-025-02889-0.
3
Favorable long-term cognitive outcomes following recurrent ARIA linked to amyloid-lowering therapies: two cases.与淀粉样蛋白降低疗法相关的复发性ARIA后的良好长期认知结果：两例病例
J Neurol. 2025 Jan 24;272(2):168. doi: 10.1007/s00415-025-12910-x.
本文引用的文献
1
Biomarker-Based Approach to α-Synucleinopathies: Lessons from Neuropathology.基于生物标志物的α-突触核蛋白病研究方法：神经病理学的经验教训
Mov Disord. 2024 Dec;39(12):2173-2179. doi: 10.1002/mds.30028. Epub 2024 Oct 3.
2
International Parkinson and Movement Disorder Society Viewpoint on Biological Frameworks of Parkinson's Disease: Current Status and Future Directions.国际帕金森病和运动障碍协会关于帕金森病生物学框架的观点：现状与未来方向
Mov Disord. 2024 Oct;39(10):1710-1715. doi: 10.1002/mds.30007. Epub 2024 Sep 9.
3
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
4
Concerns with the new biological research criteria for synucleinopathy.对新的突触核蛋白病生物学研究标准的担忧。
Lancet Neurol. 2024 Jul;23(7):660-661. doi: 10.1016/S1474-4422(24)00225-4.
5
Concerns with the new biological research criteria for synucleinopathy.对新的突触核蛋白病生物学研究标准的担忧。
Lancet Neurol. 2024 Jul;23(7):659-660. doi: 10.1016/S1474-4422(24)00213-8.
6
α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden.α-突触核蛋白种子扩增检测在疾病晚期检测到常染色体显性阿尔茨海默病中的路易体共病理，并依赖于路易体病理负担。
Alzheimers Dement. 2024 Jun;20(6):4351-4365. doi: 10.1002/alz.13818. Epub 2024 Apr 26.
7
A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria.帕金森病的生物学分类：SynNeurGe 研究诊断标准。
Lancet Neurol. 2024 Feb;23(2):191-204. doi: 10.1016/S1474-4422(23)00404-0.
8
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义：建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
9
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.突触核蛋白病生存及痴呆症发病的神经病理学和遗传学关联：一项回顾性分析
Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.
10
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers.路易体痴呆和帕金森病痴呆的边界问题：诊断、治疗、分子病理学及生物标志物
Neurology. 2007 Mar 13;68(11):812-9. doi: 10.1212/01.wnl.0000256715.13907.d3.
Zotero 插件